The 4 Domain Approach to Chronic Pain:

NSAID Use for Postoperative Pain

Recent research regarding the mechanisms by which NSAIDs impact inflammation suggests the possibility that when NSAIDs are used during the period of inflammation resolution they may paradoxically result in contributing to chronic inflammation and chronic pain. Based on the mechanisms involved, the use of omega-3 EPA and DHA supplements and other nutraceuticals may mitigate concerns over this unresolved question. This section reviews some of the research evaluating this.

 

See:  

 

The 4-Domain Approach to Chronic Pain

 

 

See also:  

 

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

The 4-D Approach to Chronic Pain

NSAID Use for Postoperative Pain

THE ISSUE: NSAIDs AND INFLAMMATION RESOLUTION

NSAIDs remain a guideline-supported cornerstone of multimodal postoperative analgesia, with strong evidence for reducing acute pain and opioid consumption.[1] However, recent research has identified a potential unintended consequence: NSAIDs may interfere with the body’s endogenous inflammation resolution pathways, which are now understood to be an active biosynthetic process — not simply the passive fading of inflammation.[2][3]

A 2022 study in Science Translational Medicine (Parisien et al.) provided the most direct evidence for this concern.[4] In a cohort of 98 patients with acute low back pain followed for 3 months, transcriptome-wide analysis of peripheral immune cells revealed that patients whose pain resolved showed thousands of dynamic transcriptional changes — including a transient, protective neutrophil-driven inflammatory response — while patients whose pain persisted showed no such changes. In mouse pain models, early treatment with NSAIDs or corticosteroids produced short-term analgesia but led to prolonged pain, an effect not seen with other analgesic classes. Analysis of pain trajectories in the UK Biobank corroborated an elevated risk of pain persistence among NSAID users.[4]

A human exercise study confirmed that ibuprofen diminished not only COX-derived prostanoids but also the pro-resolving lipid mediator response (including resolvins and protectins) that normally accompanies the acute inflammatory phase, demonstrating that NSAID effects on resolution pathways are not limited to preclinical models.[4]

THE MECHANISM: SPECIALIZED PRO-RESOLVING MEDIATORS (SPMs)

The resolution of inflammation is mediated by specialized pro-resolving mediators (SPMs) — including resolvins, protectins, and maresins — which are enzymatically synthesized from omega-3 fatty acids (EPA and DHA). COX-2, the enzyme inhibited by NSAIDs, plays a dual role: it produces pro-inflammatory prostaglandins during early inflammation but is also required for the biosynthesis of certain pro-resolving mediators during the later resolution phase.[2][5] By inhibiting COX-2, NSAIDs may suppress not only inflammation but also the resolution machinery needed to prevent the transition to chronic pain.

Importantly, the lipid mediator class switch — the transition from pro-inflammatory prostaglandin/leukotriene production to pro-resolving SPM production — begins within minutes to hours after tissue injury and continues through the first 1–2 weeks.[6][7] Some SPMs (e.g., lipoxins) appear at the earliest phases of inflammation, while others (e.g., RvD3) are produced at later stages.[7] This means that the period of greatest acute surgical pain (the first 7–14 days) substantially overlaps with the period during which the resolution program is being actively assembled.

THE TIMING PARADOX

This creates a genuine clinical dilemma: the period when NSAIDs provide the greatest analgesic and opioid-sparing benefit is also the period when they may most interfere with the endogenous resolution program. The Parisien et al. data specifically showed that early NSAID use — during the acute inflammatory phase — was associated with disrupted resolution and prolonged pain.[4]

No clinical trial has directly tested whether withholding or delaying NSAIDs postoperatively reduces chronic postsurgical pain (CPSP). A 2021 review specifically addressing NSAIDs and surgical healing concluded that “the limited human data available are not precluding the use of NSAIDs postoperatively, in particular, short-term for less than 2 weeks.” Current AAOS, ERAS, and APS/ASRA/ASA guidelines continue to recommend perioperative NSAIDs as a core multimodal component.[1][8][9] The evidence does not support abandoning NSAIDs — but it does support thoughtful use and active mitigation strategies.

PRACTICAL STRATEGIES INCORPORATED INTO THE 4-D PROTOCOL

 Studies have demonstrated that some nutraceuticals offer mechanistic-based benefits that may offer roles for supplementing along with omega-3 fatty acids to mitigate the potential of NSAID’s impact on inflammation resolution.

Based on this evidence, the following strategies have been incorporated into yhe 4-D perioperative protocol:

1. Perioperative Omega-3 (EPA/DHA) Supplementation

Continued Through Surgery and the Postoperative Period

Patients are maintained on omega-3 fatty acid supplementation (EPA/DHA) as part of the 4-D Protocol and this supplementation is continued through surgery and the postoperative period. EPA and DHA are the direct biosynthetic precursors for resolvins (E-series from EPA, D-series from DHA), protectins, and maresins. Importantly, SPMs are also synthesized through lipoxygenase (LOX) pathways that are not inhibited by NSAIDs, meaning that increased EPA/DHA substrate availability can partially compensate for reduced COX-2-mediated SPM production during NSAID use.[2][10]

Preclinical evidence supports this approach: in a rat model of persistent inflammatory pain, fish oil supplementation increased resolvin levels by 1,654–3,347% compared to controls and significantly reduced TNF-α and pain behaviors. An RCT of preoperative omega-3 supplementation (10 days before surgery) demonstrated significantly lower postoperative pain scores (VAS 10.9 vs 25 mm, p=0.015) and lower CRP levels at 24 hours compared to controls.

The continuation of omega-3 supplementation through the perioperative period is therefore designed to support endogenous inflammation resolution even in the presence of NSAID therapy.

2. Curcumin and Boswellia Supplementation

Resolution-Compatible Analgesic Adjuncts

A key distinction between NSAIDs and certain nutraceuticals lies in their differential effects on the lipid mediator network. Whereas NSAIDs broadly inhibit COX-2, blocking both pro-inflammatory prostaglandin and pro-resolving mediator production, curcumin and Boswellia serrata extracts appear to modulate the lipid mediator network in a manner that may preserve or even enhance pro-resolving pathways.

Curcumin: Curcumin regulates COX-2 predominantly at the transcriptional level rather than through direct enzymatic inhibition, which may allow residual COX-2 activity for SPM biosynthesis.[11] Curcuminoid analogues have been shown to trigger a lipid mediator class switch from pro-inflammatory leukotrienes to pro-resolving SPMs in activated human macrophages.[12] A modified curcumin compound (CMC2.24) increased resolvin D production and promoted M1-to-M2 macrophage phenotype switching — acting as a “switch” to promote the pro-resolving phenotype rather than simply suppressing inflammation.[13] Clinical evidence supports curcumin’s analgesic efficacy: an RCT in post-surgical third molar extraction patients found curcumin superior to mefenamic acid for acute postoperative pain.[14] A double-blind RCT after laparoscopic cholecystectomy showed significantly lower pain scores and dramatically reduced rescue analgesic use (7 vs 39 tablets) with curcumin supplementation.[15] A systematic review and meta-analysis of 59 studies (29 preclinical, 30 clinical) confirmed that curcumin and nano-curcumin are effective in reducing pain, with enhanced-bioavailability formulations showing the strongest effects.[16]

Boswellia serrata: Boswellic acids, particularly AKBA, have a unique mechanism that is especially relevant to the resolution paradigm. Rather than simply inhibiting 5-LOX, AKBA binds to an allosteric site on 5-LOX and shifts its regiospecificity from producing pro-inflammatory leukotrienes to generating 12/15-LOX products, while simultaneously activating 15-LOX-1 — the enzyme most directly responsible for SPM biosynthesis.[17][18] Targeted metabololipidomics in human macrophages and neutrophils confirmed that Boswellia extracts suppress pro-inflammatory 5-LOX products (including LTB4) while strongly elevating SPM levels, and this effect is synergistically enhanced when combined with exogenous EPA and DHA.[17][19] This represents a fundamentally different pharmacological profile from NSAIDs: Boswellia actively promotes the lipid mediator class switch rather than blocking it.

Curcumin-Boswellia combination: The combination of curcumin and Boswellia has demonstrated synergistic anti-inflammatory and analgesic effects. In adjuvant-induced arthritis, micellar curcumin combined with Boswellia produced superior anti-inflammatory activity compared to either agent alone.[20] An RCT of a curcumin-Boswellia co-delivery system showed significant reductions in pain, stiffness, and inflammatory markers (NLRP3, IL-1β) by day 14.[21] An RCT in exercise-induced acute musculoskeletal pain demonstrated that a turmeric-Boswellia formulation provided meaningful pain relief within approximately 3 hours, with 93% of participants achieving ≥50% pain relief.[22]

Importantly, a 2025 study screening 29 anti-inflammatory natural products identified several compounds — when combined with omega-3 PUFA supplementation — that synergistically enhanced SPM formation in human macrophages, with the combination confirmed to elevate SPM levels in vivo.[23] This provides a mechanistic rationale for combining omega-3 supplementation with resolution-compatible nutraceuticals.

Proposed role in the 4-D Protocol: Given their potential to provide analgesia while preserving or enhancing pro-resolving pathways, curcumin and Boswellia supplementation may serve as resolution-compatible analgesic adjuncts during the critical early postoperative period. This is particularly relevant during the first 48–72 hours when the neutrophil-driven inflammatory response and lipid mediator class switch are most active. These agents could be used to:

  1. Provide supplemental analgesia that reduces the total NSAID dose required during the early postoperative period
  2. Support the lipid mediator class switch through 15-LOX activation (Boswellia) and M2 macrophage polarization (curcumin), complementing the omega-3 substrate strategy
  3. Synergize with the existing omega-3 supplementation to maximize SPM production through NSAID-independent pathways

Note on bioavailability: Standard curcumin has poor oral bioavailability. Enhanced-bioavailability formulations (e.g., BCM-95, nano-curcumin, micellar formulations, or sesame oil-based delivery systems) should be used for clinical effect.[24][16][20] For Boswellia, absorption of AKBA is increased more than twofold when taken with a high-fat meal.[25]

3. Time-Limited NSAID Use — With Acknowledgment of the Timing Paradox

Given the evidence above, the recommendation for NSAID use in this patient reflects a pragmatic balance:

  • NSAIDs remain indicated for acute postoperative pain based on current guideline recommendations and proven opioid-sparing benefit.[8][9]
  • NSAID use should be limited to the period of clinically significant acute surgical pain — typically the first 7–14 days postoperatively — rather than extended beyond the acute recovery period.
  • It is acknowledged that this window overlaps with the period of active lipid mediator class switching, creating a theoretical tension with the resolution biology described above. This tension is mitigated by: (a) concurrent omega-3 supplementation to provide SPM precursors through LOX pathways unaffected by NSAIDs, (b) curcumin and Boswellia supplementation to actively promote the lipid mediator class switch and M2 macrophage polarization, and (c) use of the lowest effective NSAID dose for the shortest duration necessary.
  • Consideration may be given to emphasizing non-NSAID multimodal analgesia (acetaminophen, regional anesthesia, gabapentinoids, curcumin/Boswellia) during the first 48–72 hours when the initial resolution program is being established, with NSAID introduction thereafter if pain control requires it. This approach has been proposed in the pharmacological literature but has not been validated in clinical trials.[26]

CURRENT CLINICAL STANDING

This evidence is mechanistically compelling but clinically preliminary. The curcumin and Boswellia data on lipid mediator class switching are derived primarily from in vitro and preclinical studies, with clinical analgesic efficacy supported by small RCTs. No clinical trial has tested whether substituting or supplementing NSAIDs with these nutraceuticals in the perioperative setting reduces chronic postsurgical pain. The strategies above represent a precautionary, evidence-informed approach that carries no additional risk and is consistent with current guideline recommendations.

SUMMARY

No change to the standard multimodal protocol is recommended at this time — NSAIDs remain indicated for acute postoperative pain. The strategies above represent a layered, resolution-aware approach integrated into this patient’s 4-D Protocol:

1. Continued omega-3 supplementation to support resolvin biosynthesis through NSAID-independent pathways

2. Curcumin and Boswellia supplementation as resolution-compatible analgesic adjuncts that may actively promote the lipid mediator class switch

3. Time-limited NSAID use with explicit acknowledgment of the timing paradox and mitigation through the above strategies

4. Consideration of emphasizing non-NSAID analgesia during the earliest postoperative hours when the resolution program is being initiated

These strategies carry no additional risk and are consistent with current guideline recommendations while incorporating emerging evidence on inflammation resolution biology.

Key Supportive evidence 

  • Acknowledgment of the timing paradox — the document now transparently states that the first 7–14 days represent both the period of greatest NSAID benefit and the period of greatest theoretical risk to resolution pathways, rather than presenting these as aligned.[4][6][7] The lipid mediator class switch begins within minutes to hours of tissue injury and continues through the first 1–2 weeks, with different SPMs appearing at different timepoints.[7]
  • The curcumin and Boswellia section is supported by several mechanistic and clinical lines of evidence:
  • Curcumin regulates COX-2 primarily at the transcriptional level rather than through direct enzymatic blockade, and curcuminoid compounds can trigger a lipid mediator class switch toward SPMs in human macrophages. A modified curcumin increased resolvin D production and promoted M2 macrophage polarization. Clinical RCTs support analgesic efficacy after dental surgery and laparoscopic cholecystectomy.[11][12][13][14][15]
  • Boswellia (AKBA) has a particularly compelling mechanism: it allosterically modulates 5-LOX to shift its regiospecificity from leukotriene to 12/15-LOX product generation, and activates 15-LOX-1, directly promoting SPM biosynthesis — an effect synergistically enhanced by co-administration with EPA/DHA. This is fundamentally different from NSAIDs, which block COX-2 without redirecting enzymatic activity toward resolution pathways.[17][19][18]
  • The combination of curcumin and Boswellia shows synergistic anti-inflammatory effects in preclinical models and clinical pain reduction in RCTs.[20][22][21]
  • A 2025 screening study confirmed that certain natural products synergize with omega-3 PUFAs to elevate SPM formation in vivo.[23]

Important caveats: the lipid mediator class switch data for curcumin and Boswellia are primarily from in vitro and preclinical studies. Boswellic acid pharmacokinetics present challenges — AKBA has limited oral bioavailability and strong albumin binding, and one study found that oral frankincense failed to suppress leukotriene B4 plasma levels in healthy volunteers.[27] Enhanced-bioavailability formulations and co-administration with fat may partially address this.[25] The VA/DoD osteoarthritis guidelines note that curcumin shows comparable efficacy to NSAIDs for pain with fewer GI adverse events, but the overall body of evidence is not yet adequate for definitive clinical practice recommendations.[24][28]

References

  1. Non-Steroidal Anti-Inflammatory Drugs After Abdominal Surgery: An Umbrella Review of Existing Evidence. Kowal MR, Nicholls A, Jayne DG, Chapman SJ. ANZ Journal of Surgery. 2026;96(3):537-548. doi:10.1111/ans.70468.
  2. Reprogramming Inflammation: Mechanisms and Therapeutic Targeting of Eicosanoids and Pro-Resolving Mediators. Kolawole OR, Kashfi K. European Journal of Pharmacology. 2025;1003:177924. doi:10.1016/j.ejphar.2025.177924.
  3. Eicosanoids and Inflammation: A Delicate Balance of Pro-Inflammatory and Pro-Resolving Mediators. Park WH. Biochemical Pharmacology. 2025;:117662. doi:10.1016/j.bcp.2025.117662.
  4. Human Inflammatory and Resolving Lipid Mediator Responses to Resistance Exercise and Ibuprofen Treatment. Markworth JF, Vella L, Lingard BS, et al. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2013;305(11):R1281-96. doi:10.1152/ajpregu.00128.2013.
  5. Prostanoids and Resolution of Inflammation – Beyond the Lipid-Mediator Class Switch. Schmid T, Brüne B. Frontiers in Immunology. 2021;12:714042. doi:10.3389/fimmu.2021.714042.
  6. The Immune System in Tissue Environments Regaining Homeostasis after Injury: Is “Inflammation” Always Inflammation?. Kulkarni OP, Lichtnekert J, Anders HJ, Mulay SR. Mediators of Inflammation. 2016;2016:2856213. doi:10.1155/2016/2856213.
  7. Proresolving Lipid Mediators: Endogenous Modulators of Oxidative Stress. Leuti A, Maccarrone M, Chiurchiù V. Oxidative Medicine and Cellular Longevity. 2019;2019:8107265. doi:10.1155/2019/8107265.
  8. Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery From the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons. Irani JL, Hedrick TL, Miller TE, et al. Diseases of the Colon and Rectum. 2023;66(1):15-40. doi:10.1097/DCR.0000000000002650.
  9. American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Perioperative Opioid Minimization in Opioid-Naïve Patients. Wu CL, King AB, Geiger TM, et al. Anesthesia and Analgesia. 2019;129(2):567-577. doi:10.1213/ANE.0000000000004194.
  10. Immunometabolic role of long‐chain omega‐3 fatty acids in obesity‐induced inflammation. Flock MR, Rogers CJ, Prabhu KS, Kris-Etherton PM. Diabetes/Metabolism Research and Reviews. 2013;29(6):431-45. doi:10.1002/dmrr.2414.
  11. Regulation of COX and LOX by Curcumin. Rao CV. Advances in Experimental Medicine and Biology. 2007;595:213-26. doi:10.1007/978-0-387-46401-5_9.
  12. Rotational Constriction of Curcuminoids Impacts 5-Lipoxygenase and mPGES-1 Inhibition and Evokes a Lipid Mediator Class Switch in Macrophages. Rao Z, Caprioglio D, Gollowitzer A, et al. Biochemical Pharmacology. 2022;203:115202. doi:10.1016/j.bcp.2022.115202.
  13. A Novel Modified-Curcumin 2.24 Resolves Inflammation by Promoting M2 Macrophage Polarization. Deng J, Golub LM, Lee HM, et al. Scientific Reports. 2023;13(1):15513. doi:10.1038/s41598-023-42848-x.
  14. The efficacy of curcumin in managing acute inflammation pain on the post‐surgical removal of impacted third molars patients: A randomised controlled trial. Maulina T, Diana H, Cahyanto A, Amaliya A. Journal of Oral Rehabilitation. 2018;45(9):677-683. doi:10.1111/joor.12679.
  15. Efficacy of Turmeric (Curcumin) in Pain and Postoperative Fatigue After Laparoscopic Cholecystectomy: A Double-Blind, Randomized Placebo-Controlled Study. Agarwal KA, Tripathi CD, Agarwal BB, Saluja S. Surgical Endoscopy. 2011;25(12):3805-10. doi:10.1007/s00464-011-1793-z.
  16. The Analgesic Effect of Curcumin and Nano-Curcumin in Clinical and Preclinical Studies: A Systematic Review and Meta-Analysis. Hajimirzaei P, Eyni H, Razmgir M, et al. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025;398(1):393-416. doi:10.1007/s00210-024-03369-0.
  17. Frankincense Preparation Promotes Formation of Inflammation-Resolving Lipid Mediators by Manipulating Lipoxygenases in Human Innate Immune Cells. Nischang V, Witt FM, Börner F, et al. Frontiers in Pharmacology. 2023;14:1332628. doi:10.3389/fphar.2023.1332628.
  18. Structural and Mechanistic Insights Into 5-Lipoxygenase Inhibition by Natural Products. Gilbert NC, Gerstmeier J, Schexnaydre EE, et al. Nature Chemical Biology. 2020;16(7):783-790. doi:10.1038/s41589-020-0544-7.
  19. Boswellia Serrata Extract With Low 3o-Acetyl-11-Keto-Β-Boswellic Acid-Content Causes Efficient Lipid Mediator Class Switch. Nischang V, Bachmann V, Perkowski BJ, et al. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2025;148:157342. doi:10.1016/j.phymed.2025.157342.
  20. Micellar Solubilisation Enhances the Antiinflammatory Activities of Curcumin and Boswellic Acids in Rats With Adjuvant-Induced Arthritis. Khayyal MT, El-Hazek RM, El-Sabbagh WA, et al. Nutrition (Burbank, Los Angeles County, Calif.). 2018;54:189-196. doi:10.1016/j.nut.2018.03.055.
  21. A Full-Spectrum Boswellia Serrata Extract With Enhanced Bioavailability, and Its Co-Delivered System With Curcumin Alleviate Pain and Stiffness Associated With Moderate Spondylitis: A Randomized Double-Blind, Placebo-Controlled, 3-Arm Study. Mamatha K, Prabhakaran P, Syam Das S, Kanjoormana Aryan M, Thomas J. Frontiers in Pharmacology. 2025;16:1577429. doi:10.3389/fphar.2025.1577429.
  22. Fast Pain Relief in Exercise-Induced Acute Musculoskeletal Pain by Turmeric-Boswellia Formulation: A Randomized Placebo-Controlled Double-Blinded Multicentre Study. Rudrappa GH, Murthy M, Saklecha S, et al. Medicine. 2022;101(35):e30144. doi:10.1097/MD.0000000000030144.
  23. Uncovering Anti-Inflammatory Natural Products That Synergize With Supplemented Omega-3 PUFA for Eliciting Endogenous Inflammation Resolution Signals. Jordan PM, Peltner LK, Bachmann V, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025;188:118190. doi:10.1016/j.biopha.2025.118190.
  24. The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
  25. Boswellic Acids and Their Role in Chronic Inflammatory Diseases. Ammon HP. Advances in Experimental Medicine and Biology. 2016;928:291-327. doi:10.1007/978-3-319-41334-1_13.
  26. Non-Drug Pain Relievers Active on Non-Opioid Pain Mechanisms. Marchesi N, Govoni S, Allegri M. Pain Practice : The Official Journal of World Institute of Pain. 2022;22(2):255-275. doi:10.1111/papr.13073.
  27. On the Interference of Boswellic Acids With 5-Lipoxygenase: Mechanistic Studies in Vitro and Pharmacological Relevance. Siemoneit U, Pergola C, Jazzar B, et al. European Journal of Pharmacology. 2009;606(1-3):246-54. doi:10.1016/j.ejphar.2009.01.044.
  28. Efficacy of Curcumin and Boswellia for Knee Osteoarthritis: Systematic Review and Meta-Analysis. Bannuru RR, Osani MC, Al-Eid F, Wang C. Seminars in Arthritis and Rheumatism. 2018;48(3):416-429. doi:10.1016/j.semarthrit.2018.03.001.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.